OpGen, Inc. (OPGN)
NASDAQ: OPGN · IEX Real-Time Price · USD
0.460
-0.025 (-5.15%)
May 3, 2024, 11:50 AM EDT - Market open
OpGen Revenue
OpGen had revenue of $3.07M in the twelve months ending September 30, 2023, down -7.28% year-over-year. Revenue in the quarter ending September 30, 2023 was $699.02K with 55.78% year-over-year growth. In the year 2022, OpGen had annual revenue of $2.61M, a decrease of -39.45%.
Revenue (ttm)
$3.07M
Revenue Growth
-7.28%
P/S Ratio
1.99
Revenue / Employee
$36,120
Employees
85
Market Cap
5.81M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 2.61M | -1.70M | -39.45% |
Dec 31, 2021 | 4.31M | 91.59K | 2.17% |
Dec 31, 2020 | 4.21M | 715.83K | 20.46% |
Dec 31, 2019 | 3.50M | 552.31K | 18.75% |
Dec 31, 2018 | 2.95M | -264.70K | -8.24% |
Dec 31, 2017 | 3.21M | -814.68K | -20.24% |
Dec 31, 2016 | 4.03M | 867.97K | 27.49% |
Dec 31, 2015 | 3.16M | -968.66K | -23.47% |
Dec 31, 2014 | 4.13M | 1.72M | 71.18% |
Dec 31, 2013 | 2.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BIOLASE | 49.16M |
Regional Health Properties | 17.16M |
ThermoGenesis Holdings | 9.45M |
Aditxt | 645.18K |
Silo Pharma | 72.10K |
OPGN News
- 3 days ago - OpGen Provides Update on Business Operations and Strategic Opportunities - GlobeNewsWire
- 9 days ago - OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K - GlobeNewsWire
- 5 weeks ago - OpGen Announces Acquisition of Preferred Stock by David Lazar - GlobeNewsWire
- 6 months ago - OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds - GlobeNewsWire
- 9 months ago - OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering - GlobeNewsWire
- 9 months ago - OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement - GlobeNewsWire